Pt-ATP as an antineoplastic agent in an experimental mice model system

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Platinum complexes are widely studied for their antineoplastic properties.
• Ehrlich ascites carcinoma (EAC) is a common model for evaluating anticancer agents.
• Understanding the mechanism of action and toxicity profile is crucial for drug development.

Purpose of the Study:

• To evaluate the antineoplastic activity of a novel platinum complex, K4 (Pt Cl2 ATP) (Pt-ATP).
• To assess the efficacy of Pt-ATP in both ascitic and solid Ehrlich ascites carcinoma tumor models.
• To investigate the in vitro mechanism of action and in vivo toxicity of Pt-ATP.

Main Methods:

• Administration of Pt-ATP at a total dose of 10 mg/kg body weight to tumor-bearing mice.
• Assessment of tumor burden inhibition in both ascitic and solid EAC models.
• In vitro evaluation of (3H) thymidine incorporation into EAC tumor cells in the presence of Pt-ATP.
• Analysis of peripheral blood cells, bone marrow, and spleen for toxic effects.

Main Results:

• Pt-ATP significantly inhibited tumor burden in both ascitic and solid EAC models.
• A notable increase in host lifespan was observed following Pt-ATP treatment.
• In vitro studies confirmed that Pt-ATP inhibits (3H) thymidine incorporation in EAC tumor cells, suggesting interference with DNA synthesis.
• No significant toxic effects were observed on peripheral blood cells, bone marrow, or spleen cellularity.

Conclusions:

• The platinum complex K4 (Pt-ATP) exhibits potent antineoplastic activity against Ehrlich ascites carcinoma.
• Pt-ATP demonstrates a favorable safety profile with minimal toxicity to host tissues.
• Pt-ATP represents a promising candidate for further investigation as an anticancer therapeutic.